Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | S1PR2 | O95136 | 5/20 | 0.39 |
| ▸ | S1PR4 | O95977 | 5/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.39 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24672596 | 0.88 | ALDH1A1 (0.45) | PAOXEPHX1ALDH1A1TSHRS1PR2 | |
| SCHEMBL24193686 | 0.86 | DNM1 (0.44) | EPHX2S1PR2S1PR1S1PR3S1PR5 | |
| SCHEMBL20349291 | 0.86 | DNM1 (0.44) | EPHX2S1PR2S1PR1S1PR3S1PR5 | |
| SCHEMBL13715995 | 0.82 | CA12 (0.40) | EPHX2ALDH1A1TSHRBRD4 | |
| SCHEMBL22794389 | 0.81 | PAOX (0.47) | PAOXEPHX1EPHX2ALDH1A1TSHR | |
| SCHEMBL25467441 | 0.77 | ALDH1A1 (0.48) | PAOXEPHX1EPHX2ALDH1A1TSHR | |
| SCHEMBL8356699 | 0.75 | EPHX2 (0.51) | PAOXEPHX2ALDH1A1DNM1 | |
| SCHEMBL25725928 | 0.75 | BRD4 (0.34) | PAOXKDM4EBRD4 | |
| SCHEMBL23560304 | 0.74 | TSHR (0.43) | PAOXEPHX1EPHX2ALDH1A1TSHR | |
| SCHEMBL9010937 | 0.73 | RIPK1 (0.37) | ALDH1A1TSHRBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352350-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | PAOX 1862/4885EPHX1 1684/4885EPHX2 1890/4885 |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | PAOX 1862/4885EPHX1 1684/4885EPHX2 1890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.